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BACKGROUND: Elevation of FSH is frequently a consequence of impaired ovarian follicle growth. Down-regulation
of the FSH levels by inhibins is mediated through its receptor betaglycan in the gonadotrophs. Understanding of
germline status of the betaglycan gene (TGFBR3) is essential for ovarian failure pathophysiology. METHODS:
Sequence analysis was performed for the coding region of TGFBR3 gene in a cohort of 196 ovarian failure cases that
include 133 premature ovarian failure (POF) cases, 63 primary amenorrhoea (PA) cases compared with 200 controls.
RESULTS: Forty-six variants including six novel exonic variants and 16 novel intronic variants were revealed. Two
variants were missense: (i) p.Iso184Val in a control and (ii) p.Pro775Ser in a POF case. Genotypic distribution of
three variants (c.382-81C>T, c.382-77T>C and c.1200G>A) was significantly different in the patients as compared
with the controls. Five variants c.382-81C>T, c.382-77T>C, c.566-216G>A, c.1200G>A and c.2022T>C were chosen
for haplotyping. The CCAAT haplotype was significantly higher in the patient population as compared with the con-
trols (P = 0.00007). CONCLUSION: This study establishes the first mutational report of the TGFBR3 gene in correla-
tion with ovarian failure. Significant diversity of genotype distribution and haplotype analysis suggested
susceptibility of the TGFBR3 gene for ovarian failure aetiology.
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Introduction
Clinically, premature ovarian failure (POF, MIM311360) is
described as an unexplained amenorrhoea (>6 months) with
elevated levels of gonadotrophins (FSH >40 IU/l) before the
age of 40 years. It occurs in ∼1% women. Various compre-
hensive studies have been reported at the chromosomal as well
as the gene level to elucidate the aetiology of ovarian failure,
but it still remains elusive (Schlessinger et al., 2002). Extensive
germline studies have revealed very few mutations in the gona-
dotrophins and their corresponding receptors except notewor-
thy missense variant p.Ala189Val in the extracellular domain
of the FSH receptor (FSHR) gene. This variant was strongly
associated with ovarian failure in the Finnish population
(Aittomaki et al., 1995). This variant is rare in other world
populations. The truncated variants of the FOXL2 gene were asso-
ciated with familial Type 1 blepharophimosis–ptosis–epicanthus
inversus syndrome (BPES) cases where females inherit ovarian
failure (Crisponi et al., 2001). Several FOXL2 gene mutations
have been reported in the Type 1 BPES and non-syndromic
POF cases but are uncommon in diverse populations (De Baere
et al., 2005). The first germline study of the inhibin alpha
(INHa) gene revealed a distinct missense mutation c.769G>A
(p.Ala253Thr) in its mature peptide region (Shelling et al.,
2000). Various population studies including the Indian popula-
tion corroborated the significant presence of this mutation in
ovarian failure cases with almost absence in the controls
(Shelling et al., 2000; Marozzi et al., 2002; Dixit et al., 2004).
Substantial significance of this mutation as a genetic marker
for ovarian failure strongly urges germline studies of other key
molecules networked around inhibin functions.
Inhibins are the most important factors directly involved in
the down-regulation of FSH by a negative feedback mecha-
nism. Failure to modulate FSH levels results in a diminished
ovarian reserve and clinically characterized as hypergonado-
trophic hypogonadism or POF (Welt et al., 2005). The regulation
of FSH levels is maintained by opposing actions of both inhib-
ins and activins. These growth factors are mainly produced by
granulosa cells in the ovary. These factors feedback on the
FSH-producing gonadotrophs in the anterior pituitary. The
activins bind their Type II receptors (ActRIIA and ActRIIB)
located on the gonadotroph cell surface. The activin/ActRII
complex further recruits Type I receptor ALK4. This activin/
ActRII/ALK4 complex in turn activates Smad2/3 signalling
and results in an elevated production of FSH. Conversely,
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inhibins bind to a Type III receptor betaglycan located on the
gonadotrophs. This inhibin/betaglycan complex has an equal
binding affinity for activin Type II receptors and therefore
competes with activin-mediated signalling. Unlike activin/
ActRII complex, the inhibin/betaglycan/ActRII complex fails
to recruit ALK4 because of the lack of kinase activity in the
cytoplasmic domain of betaglycan. This inhibin-mediated phe-
nomenon is incompetent to initiate Smad signalling resulting in
the down-regulation of FSH production (Lewis et al., 2000).
The betaglycan receptor is a 300-kDa protein, which is
expressed in a variety of tissues including reproductive and
pituitary tissues. The expression of betaglycan mRNA and
receptor in gonadotrophs fluctuates sharply with menstruation
cycle stages, inhibin, FSH and estradiol (E2) levels (Chapman and
Woodruff, 2003). Recent reports on the betaglycan receptor
could successfully solve the mystery of inhibin action mechanism
(Phillips and Woodruff, 2004). Germline mutations in the betagly-
can gene (TGFBR3) may result in its altered mRNA expression,
structure and binding affinity. These alterations would be antici-
pated to lead to the loss of inhibin-mediated FSH down-regulation.
This study has been designed to uncover germline status of the
TGFBR3 gene in the cases of ovarian failure. Standard experi-
ments were designed to obtain DNA sequencing data of all the
exons. In sillico sequence analysis and various statistical
parameters were designed to establish the germline status.
Materials and methods
Patient and control recruitment
One hundred and ninety-six patients with ovarian failure were
recruited, which included non-familial POF cases (n = 121), familial
POF cases (n = 12), non-familial PA cases (n = 56) and familial PA
cases (n = 7). These patients were recruited at the Infertility Institute
and Research Centre (IIRC), Hyderabad, and the Institute of Repro-
ductive Medicine (IRM), Kolkata. Patients disclaiming any familial
history of ovarian failure were categorized as non-familial/sporadic
cases. Patients with the family history of ovarian failure in the same
generation or parental generation were considered as familial cases.
The diagnostic criteria for POF following the definition include at
least 6 months of amenorrhoea before the age of 40 years, with high
serum FSH levels (>40 IU/l). The criterion for PA is defined as a con-
dition with complete absence of menses or only induced menses. All
the patients were assessed clinically, with complete medical and
gynaecological history, including the history of menses, age at meno-
pause, serum FSH levels (three times at 1-month interval), LH levels,
TSH levels, and with no history of any autoimmune disease. Res-
pective consent forms from these patients were collected by the
concerned clinic. Karyotyping with a high-resolution GTG banding
was carried out for all the patients and controls for chromosomal
anomalies. Patients and controls with chromosomal abnormalities
were excluded from the study. Normal healthy females with regular
menstrual history, normal FSH levels and successful pregnancies
were recruited as controls (n = 200). Recruitment of the controls was
entirely population-based to support the study. The Institutional
Review Board of Centre for Cellular and Molecular Biology (CCMB),
Hyderabad, approved the study.
DNA extraction and karyotyping
A 5-ml aliquot of peripheral blood was collected in EDTA vacutainers
for genomic DNA isolation, and another 5 ml of peripheral blood was
collected in heparin vacutainers for chromosomal analysis. DNA was
extracted using the Nucleon BACC2 DNA extraction kit (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) according to the manufac-
turer’s protocol. Chromosomal analysis was performed on phytohae-
magglutinin (PHA)-stimulated peripheral lymphocyte cultures using
standard conventional cytogenetic methods.
PCR
The TGFBR3 gene is comprised of 16 exons. Primers for all the exons
were designed using online Genefisher software (http://bibiserv.techfak.
uni-bielefeld.de/genefisher). All the PCR conditions included initial
denaturation at 94°C for 5 min, cyclic denaturation at 94°C for 45 s
and extension at 72°C for 1 min with total 35 cycles. All the primer
sequences, with their corresponding annealing temperatures, are sum-
marized in Table I. The presence of all sequence variants was con-
firmed by performing three independent PCR reactions and subsequent
DNA sequencing.
DNA sequencing and analysis
All the PCR products were obtained using the above-mentioned prim-
ers, amplifying the corresponding exon and flanking regions of
the gene. Sequencing was performed using the Big Dye terminator
sequencing protocol, supported by Applied Biosystems using an ABI
prism 3730xl DNA analyzer. The obtained sequence data were ana-
lysed using sequence analysis and autoassembler software in MacOS.
The reference TGFBR3 sequence was downloaded from Ensembl
database (www.ensembl.org/Homo_sapiens/index.html). The Human
Genome Variation Society (HGVS) guidelines were followed for all
the variant nomenclature and genotype representation throughout the
text and tables.
Statistical analysis of results
SNPAlyzerTM 5.0 software was used for performing the Hardy–Weinberg
disequilibrium, Fisher’s exact test, odds ratio, confidence intervals
and chi-square test. Online ISTECH SNPAnalyzer software was used
for haplotyping. Multinomial logistic regression analysis was per-
formed using SPSS 11.0 software.
Results
The sequencing data collection and analysis was successfully
performed for the coding regions of TGFBR3 gene in all the
cases and controls, which included non-familial POF cases
(n = 121), familial POF cases (n = 12), non-familial PA cases
(n = 56), familial PA cases (n = 7) and controls (n = 200). The
patients as well as the control populations were in Hardy–
Weinberg equilibrium for all the genetic variations. The post
hoc power analysis confirmed the good strength of patient and
control populations for this study. In the POF cases, the mean
age of attaining amenorrhoea was 26 years (range 14–40
years), mean FSH level was 59.3 IU/l and mean LH level was
33.7 IU/l. Women with regular menstrual cycles, successful
pregnancies and normal FSH levels (4–11 IU/l) were recruited
as controls (age range 30–45 years). The control group mean
FSH level was 7.3 IU/l and mean age 37 years.
This study revealed 46 sequence variants including 22 novel
variants. All the sequence variants were confirmed by the repe-
tition of three independent PCR and sequencing reactions,
including sequencing in the reverse direction also. The novel
variants include six exonic variants and 16 intronic variants.
The details of all the variants have been summarized in Table II.
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Two novel coding variants were missense, i.e. c.550 A>G
(p.Iso184Val) in a control and c.2323C>T (p.Pro775Ser) in
a POF case. On the basis of Fisher’s exact test, allelic frequen-
cies for three variants were almost significantly diverse in
cases of ovarian failure than in controls as given below: (i)
c.382-81C>T (P = 0.0136 for POF and P = 0.0606 for PA), (ii)
c.382-77T>C (P = 0.0136 for POF, P = 0.0606 for PA) and
(iii) c.1200G>A (P = 0.0669 for POF and P = 0.0875 for PA).
The genotypic distribution for these three variants was also sig-
nificantly varied (95% confidence level) in patients as com-
pared with controls as summarized in Table III. Notably, the
C allele of c.382-81C>T variant was always linked with the
C allele of c.382-77T>C and vice versa. Unconditional multi-
nomial logistic regression analysis was performed for the
c.382-81C>T variant and c.1200G>A variant to estimate the
relative risk for ovarian failure. These variants were chosen for
regression analysis considering significant genotypic differ-
ences in the patients as compared with the controls at 95% con-
fidence limits. The c.382-77T>C variant was not chosen for
regression analysis because of its complete linkage with the
c.382-81C>T variant. The multinomial regression model was
significant for both the patient populations (P < 0.00005 for
POF and P = 0.007 for PA) as compared with the controls with
a pseudo-R2 value (Nagelkerke) of 0.04. Both the genotypes
showed almost significant regression P values as summarized
in Table IV. On the basis of high frequency of minor allele
(>5%) and the significant differences in genotype distribution
at 80% confidence level (P < 0.2), five variants, namely c.382-
81C>T, c.382-77T>C, c.566-216G>A, c.1200G>A and
c.2022T>C, were chosen for haplotyping. The criterion for
using 80% confidence limit was not to represent the associa-
tion status of individual variants but rather to restrict variants
for their cumulative effects. The variants other than these five
were either rare or showed almost similar genotypic distribu-
tion among the patients and the controls. The details of these
five variants with varied genotypic distribution in either POF
cases or PA cases as compared with the controls are summa-
rized in Table III. The significance of the haplotype analysis
was represented following the Bonferroni’s correction guide-
lines. The CCAAT haplotype was significantly higher in the
patients as compared with the controls (P = 0.00007). The
TTAGT haplotype was significantly higher in the controls than
in patients (P = 0.001). Other less frequent haplotypes like
CCGAC and TTAAT were only present in the patients (P =
0.0096 and 0.0003, respectively). The details of all haplotyping
analysis are summarized in Table V.
Discussion
POF is largely considered a heterogeneous genetic disorder.
The elevation of serum FSH levels is a prominent clinical fea-
ture of POF. Normal cyclic pulses of the serum FSH levels are
regulated by opposing actions of activins and inhibins. This
antagonistic activity of inhibins against activins was first
Table I. Primer details and corresponding annealing temp details for the TGFBR3 gene
aExons 10 and 11 were co-amplified because of short intron region.
bFull untranslated region (UTR) of exon 16 was not amplified.
Primer Sequence Product size (bp) Exon (length in bp) Annealing temperature 
(45 s) (°C)
BTG01F TAGAAAGCGCAGAGCTAGGTTTGG 173 Exon 1 (10) 57
BTG01R GGATAATAACAGGATCTGCCCCAT
BTG02F GCTTTTTGGCCACTTAGTCTTGG 600 Exon 2 (231) 65
BTG02R CAAAGTGCTGAGATTACAGGTGTG
BTG03F TGGCAGGGAGCTAAATCATGC 594 Exon 3 (138) 63
BTG03R GCCTCTGCCCACAGAAGATG
BTG04F GACTAGGCTTGGGATTATTCCTTG 600 Exon 4 (184) 65
BTG04R AATCCCACACAACAACCTTCTC
BTG05F CAGACGAGGACAGGAAGTATCAC 600 Exon 5 (169) 64
BTG05R CATCTGATGAAGCACACCTGAAG
BTG06F ACAGTGGCTGCATTAAGTAACC 600 Exon 6 (148) 62
BTG06R TGGGTCCGTCTTAATCCAAGG
BTG07F CGTTCTTAGCCCAAGGAAAACAG 599 Exon 7 (190) 63
BTG07R GTCATTAGGTGTCTCGGAGAGAAG
BTG08F AAAGCCACTGAGCTAGTTAGAGAG 734 Exon 8 (335) 68
BTG08R TTGACACACAAGGATCTGGAACC
BTG09F GTTCCTGTTGTTCTCAGTGACAG 499 Exon 9 (153) 65
BTG09R TGGGGTGAAAACCCTCTTCATC
BTG10 and 11F CTTGAACCTGCATTGGGTTTCTC 709 Exons 10 and 11 (141 and159)a 67
BTG10 and 11R GGAACTATAGCCCAGCACTAACC
BTG12F GCCTAAAGTGAAAGTGAGATGC 597 Exon 12 (300) 62
BTG12R CCTCCATGGAAAAGCGTCTTG
BTG13F TTGCATCTTCAGGTACAACC 595 Exon 13 (121) 60
BTG13R TTTGAATGCAAGGGAGAGTG
BTG14F AAGTGTCAGTTTCTGCTGAGAC 297 Exon 14 (42) 62
BTG14R AGCAGGGATAAACAAAGGACAG
BTG15F TTGCAATGCATGATGCAGAC 390 Exon 15 (108) 60
BTG15R AGCGGCTAAATTTCACCAAC
BTG16F AGAAGGTATTCCAGCCATCTAGG 390 Exon 16 (253)b 59
BTG16R CACTCTGTCTTTACAAGGGAACC
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explained by their direct binding competition for activin Type II
receptor (Martens et al., 1997). The direct binding affinity of
inhibins to the activin Type II receptor is ∼10-fold lower than
the activin-binding affinity for this receptor. Conversely, in vivo
equimolar or even lower serum inhibin concentrations are able
to antagonize activin activity with equal strength, suggesting
the presence of a separate inhibin receptor (Lewis et al., 2000).
Lewis et al. (2000) reported betaglycan as a first inhibin-
specific receptor that satisfies all the receptor criteria. This
receptor binds inhibins with high affinity. This inhibin/betagly-
can complex is equally capable of competing with activin for
its binding with Type II activin receptor. This complex of
inhibin/betaglycan/ActRII is unable to recruit Type I receptor
ALK4 and subsequently FSH secretion (Lewis et al., 2000). In situ
hybridization analyses of rat tissues confirmed localized
expression of the betaglycan mRNA and protein in anterior and
intermediate lobes of pituitary, oocytes, granulosa cells and
theca cells. The inhibin target cells, i.e. gonadotrophs, showed
97% immunoreactivity for betaglycan co-expression (MacConell
et al., 2002). The co-localization studies of FSHb and betagly-
can in the gonadotrophs illustrated an increased expression of
betaglycan with high serum inhibin levels while being
inversely correlated with serum FSH levels. In the ovary, prim-
ary follicles presented light hybridization signal for the
betaglycan, whereas more moderate levels were seen in follicu-
lar granulosa, thecal cells as well as the oocytes. The ovarian
interstitial cells present high levels of signal for the betaglycan
(Chapman and Woodruff, 2003). The regulatory effect of FSH
and E2 on the betaglycan mRNA transcript was evaluated in
cultured rat granulosa cells. Both FSH and E2 synergistically
Table II. Details of variations revealed during sequence analysis of the TGFBR3 gene
AA, amino acid; PA, primary amenorrhoea; POF, premature ovarian failure; CNT, controls.
aSignificant fisher’s exact test (95% confidence level).
S. No. db SNP reference ID Mutation Position AA change POF PA CNT
1 rs17881268 c.11–3C>T Intron 1 – 8/133 4/63 11/200
2 rs2810904 c.213A>G Exon 2 p.Ala71Ala 108/133 52/63 165/200
3 rs11165441 c.244–40C>T Intron 2 – 5/133 5/63 9/200
4 rs3738441 c.381+103G>A Intron 3 – 46/133 20/63 64/200
5 rs284176 c.381+194C>T Intron 3 – 133/133 63/63 198/200
6 rs111653777 c.382–118G>A Intron 3 – 50/133 25/63 78/200
7 rs10874913 c.382–112A>G Intron 3 – 133/133 63/63 200/200
8 Novel 01 c.382–96G>A Intron 3 – 1/133 0/63 0/200
9 rs12124904 c.382–81C>T Intron 3 – 19/133a 9/63 52/200
10 rs11165376 c.382–77T>C Intron 3 – 133/133a 62/63 195/200
11 Novel 02 c.382–67C>G Intron 3 – 0/133 0/63 1/200
12 Novel 03 c.550A>G Exon 4 p.Iso184Val 0/133 0/63 1/200
13 Novel 04 c.565+31G>A Intron 4 – 2/133 1/63 3/200
14 rs2306887 c.565+115A>G Intron 4 – 30/133 10/63 45/200
15 Novel 05 c.565+137C>G Intron 4 – 0/133 1/63 0/200
16 rs17880797 c.565+140C>A Intron 4 – 1/133 1/63 2/200
17 rs2306886 c.565+222C>T Intron 4 – 86/133 45/63 128/200
18 Novel 06 c.566–253A>C Intron 4 – 133/133 63/63 200/200
19 rs10783003 c.566–216G>A Intron 4 – 132/133 62/63 197/200
20 rs10783002 c.566–71C>T Intron 4 – 127/133 55/63 187/200
21 Novel 07 c.734+82C>T Intron 5 – 1/133 0/63 0/200
22 Novel 08 c.882+85T>C Intron 6 – 2/133 1/63 0/200
23 Novel 09 c.882+150A>G Intron 6 – 1/133 0/63 0/200
24 Novel 10 c.883–53T>A Intron 6 – 1/133 0/63 0/200
25 rs17878768 c.1200G>A Exon 8 p.Pro400Pro 101/133 49/63 132/200
26 Novel 11 c.1335C>T Exon 8 p.Ser445Ser 0/133 1/63 1/200
27 Novel 12 c.1408–205T>G Intron 8 – 1/133 0/63 0/200
28 rs2279455 c.1408–164G>A Intron 8 – 48/133 28/63 80/200
29 Novel 13 c.1408–115G>A Intron 8 – 5/133 4/63 9/200
30 Novel 14 c.1408–68A>G Intron 8 – 0/133 0/63 1/200
31 Novel 15 c.1408–26_1408 Intron 8 – 0/133 0/63 1/200
–25insCCC
32 Novel 16 c.1560+27G>C Intron 9 – 3/133 0/63 0/200
33 Novel 17 c.1923A>G Exon 12 p.Pro641Pro 0/133 0/63 1/200
34 rs17884995 c.2022T>C Exon 12 p.Phe674Phe 57/133 21/63 94/200
35 rs11165300 c.2160+137A>C Intron 12 – 30/133 18/63 55/200
36 rs11466603 c.2160+147G>C Intron 12 – 0/133 0/63 1/200
37 rs284869 c.2160+188G>T Intron 12 – 133/133 63/63 200/200
38 rs2038931 c.2161–75C>T Intron 12 – 13/133 7/63 23/200
39 Novel 18 c.2202G>A Exon 13 p.Ser734Ser 1/133 0/63 0/200
40 rs284878 c.2241T>C Exon 13 p.Thr747Thr 133/133 63/63 200/200
41 Novel 19 c.2280+56A>G Intron 13 – 0/133 0/63 1/200
42 Novel 20 c.2323C>T Exon 14 p.Pro775Ser 1/133 0/63 0/200
43 Novel 21 c.2430+159T>A Intron 15 – 1/133 0/63 0/200
44 rs17879140 c.2430+204_2430 Intron 15 – 13/133 4/63 15/200
+205insTTGT
45 Novel 22 c.2567C>A Exon 16 UTR 3/133 3/63 8/200
46 rs17878586 c.2568G>A Exon 16 UTR 29/133 8/63 37/200
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up-regulate its transcript levels by increasing mRNA stability
(Omori et al., 2005). These results suggest that apart from FSH
regulation in the gonadotrophs, betaglycan may also have a
locally important role in ovarian follicle proliferation and
oocyte maturation, but further research is required to elucidate
such a role.
The earliest mutation study of the TGFBR3 (betaglycan)
gene reported 12 variants including one triple-nucleotide inser-
tion (Zippert et al., 2000). This study was performed using
mRNA and genomic DNA isolated from six healthy Caucasian
individuals and 20 healthy Caucasian individuals, respectively.
This study provides the first case–control study to investigate
the role of TGFBR3 gene in genetic aetiology of ovarian fail-
ure. The mutational analysis was performed for the TGFBR3
gene-coding regions and respective flanking intronic regions
that were PCR amplified in cases of ovarian failure and con-
trols (details in Materials and methods). This study revealed
46 sequence variants including 22 novel variants. These novel
variants included six exonic variants and 16 intronic variants.
Of all the variants revealed in this study, only two variants
c.1200G>A and c.2022T>C were similar to previously pub-
lished variants by Zippert et al. (2000). Other reported variants
were documented in the SNP database during genome
sequencing projects. Two novel exonic variants were missense
as follows: (i) c.550A>G (p.Iso184Val) in a control and
(ii) c.2323C>T (p.Pro775Ser) in a POF case. The missense
variant c.550A>G was non-conserved among all present avail-
able vertebrates sequences but seems to lack an apparent func-
tional effect because of the substitution by the same group
amino acid. The wild-type c.2323C (also p.775Pro) was found
to be conserved among the present available primate sequences
but not to other vertebrate sequences. This mutation results in
the substitution of an imino proline to hydroxyl group contain-
ing serine which may cause some functional defects in the pro-
tein activity. The patient harbouring c.2323C>T variant was
genotypically heterozygous with FSH (82 IU/l), LH (43 IU/l)
and TSH (2.6 mIU/l) hormone levels. Two variants represented
Table III. Genotype distribution of three variants in POF and PA cases as compared with controls
aSignificant P value at 95% confidence interval.
bSignificant P value at 80% confidence interval.
SNP and genotype Number of subjects with genotype [n (%)]
POF PA Controls
c.382–81C>T c2 = 8.410; P = 0.0170a χ2 = 3.704; P = 0.1569b
CC 114/133 (85.7) 54/63 (85.7) 148/200 (74.0)
CT 19/133 (14.3) 8/63 (12.7) 47/200 (23.5)
TT 0/133 (0.0) 1/63 (1.6) 5/200 (2.5)
c.382–77T>C χ2 = 8.410; P = 0.0170a χ2 = 3.704; P = 0.1569b
TT 0/133 (0.0) 1/63 (1.6) 5/200 (2.5)
TC 19/133 (14.3) 8/63 (12.7) 47/200 (23.5)
CC 114/133 (85.7) 54/63 (85.7) 148/200 (74.0)
c.566–216G>A χ2 = 3.729; P = 0.155b χ2 = 0.354; P = 0.838
GG 1/133 (0.8) 1/63 (1.6) 3/200 (1.5)
GA 25 (18.8) 9/63 (14.3) 23/200 (11.5)
AA 107 (80.4) 53/63 (84.1) 174/200 (87)
c.1200G>A χ2 = 20.80; P = 0.00003a χ2 = 18.68; P = 0.00009a
GG 44/133 (33.1) 23/63 (36.5) 25/200 (12.5)
GA 57/133 (42.8) 26/63 (41.3) 107/200 (53.5)
AA 32/133 (24.1) 14/63 (22.2) 68/200 (34.0)
c.2022T>C χ2 = 1.245; P = 0.536 χ2 = 3.97; P = 0.137b
TT 76/133 (57.1) 42/63 (66.7) 106/200 (53)
TC 49/133 (36.8) 18/63 (28.6) 85/200 (42.5)
CC 8/133 (6.0) 3/63 (4.8) 9/200 (4.5)
Table IV. Logistic regression analysis of the influences of different genotypes 
and their combination on ovarian failure
PA, primary amenorrhoea; POF, premature ovarian failure.
aSignificant P value.
Patient group Genotype Odds ratio P value Pseudo-R2
POF Intercept 0.007a
c.382–81 = M/Hz 0.477 0.013a
c.382–81 = W 0.042a
c.1200 = M/Hz 1.614 0.06
c.1200 = W
PA Intercept <0.00005a
c.382–81 = M/Hz 0.476 0.061
c.382–81 = W 0.04a
c.1200 = M/Hz 1.796 0.085
c.1200 = W
Table V. Haplotype frequencies in patients groups compared with controls
PA, primary amenorrhoea; POF, premature ovarian failure.
aSignificant P value after the Bonferroni’s correction (P < 0.0125).
Haplotype POF PA Controls χ2 P value
CCAAT 0.4161 0.4533 0.2814 19.066 0.000072a
CCAGT 0.2989 0.2682 0.3663 6.146 0.046
CCAGC 0.0996 0.1110 0.1252 1.317 0.517
CCAAC 0.0611 0.0477 0.0541 0.312 0.855
TTGAC 0.0334 0.0183 0.0274 0.703 0.703
CCGAC 0.0255 0.0135 0.0000 9.293 0.009a
TTAGC 0.0185 0.0000 0.0295 4.228 0.121
TTGGT 0.0152 0.0285 0.0066 3.417 0.181
CCGGT 0.0121 0.0128 0.0301 3.968 0.137
TTAGT 0.0043 0.0081 0.0497 13.845 0.001a
TTAAT 0.0000 0.0244 0.0000 15.917 0.00034a
TTAAC 0.0000 0.0000 0.0212 7.92 0.019
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significantly diverse genotypic distribution (95% confidence
level) particularly in POF cases but not in PA cases than in
controls as detailed: (i) c.382-81C>T (P = 0.0170 for POF and
P = 0.1569 for PA) and (ii) c.382-77T>C (P = 0.0170 for POF
and P = 0.1569 for PA). The c.1200G>A variant represented
significantly different genotype distribution in both the patient
populations (POF cases and PA cases) than in the controls (P =
0.00003 for POF and P = 0.00009 for PA). Notably, the signi-
ficant diversion of this variation was not obvious at 95% con-
fidence limits with the Fisher’s exact test. The logistic
regression analysis of c.382-81C>T and c.1200G>A variants
was significant among cases of ovarian failure (P < 0.00005
for POF and P = 0.007 for PA) with a pseudo-R2 value
(Nagelkerke) of 0.04. Both the genotypes showed almost signi-
ficant regression P values as summarized in Table IV. The
haplotype analysis was performed using five variants, namely
c.382-81C>T, c.382-77T>C, c.566-216G>A, c.1200G>A and
c.2022T>C as detailed in the Results. The Bonferroni’s correc-
tion of multiple comparison was performed for haplotype ana-
lysis to set the significant P value (P < 0.0125) at 95%
confidence level. The CCAAT haplotype was most signifi-
cantly over-represented in the patients as compared with the
controls (P = 0.00007). The TTAGT haplotype was signifi-
cantly higher in the controls than in patients (P = 0.001). Other
less frequent haplotypes like CCGAC and TTAAT were only
present in the patients (P = 0.0096 and 0.0003 respectively).
In conclusion, this study provides the first germline case–
control status of the TGFBR3 gene to support the aetiology of
ovarian failure. This study presents a spectrum of 46 sequence
variants that include six novel exonic variants and 16 novel
intronic variants. So far, only two variants have been reported
as a published work, whereas the remaining known variants
have been documented during genome sequencing. The geno-
typic distributions were significantly varied for c.382-81C>T,
c.382-77T>C and c.1200G>A variant, suggesting their pos-
sible importance in the genetic aetiology of ovarian failure.
The haplotype analysis represented the significant association
of major CCAAT haplotype with ovarian failure. In conclusion,
the TGFBR3 gene may contribute to the aetiology of ovarian
failure, possibly with other genetic and environmental factors.
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